Skip to main content

Lyell Immunopharma Inc(LYEL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Globe Newswire - Tue Mar 29, 2022

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported fourth quarter and full year 2021 financial results and provided business highlights.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe